

# Evaluation of Venous Thromboembolism Prophylaxis in Patients with Moderate to Severe Traumatic Brain Injury



Andrea Feere, B.Sc.(Pharm); Jennifer Haymond, B.Sc.(Pharm), ACPR, Pharm.D.; Flora Young, B.Sc.(Pharm), ACPR, Pharm.D.

## Background

- Traumatic brain injury (TBI) is a significant risk factor for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE)
- The incidence of DVT in patients with TBI without VTE prophylaxis is reported as high as 54%
- Pharmacological prophylaxis is often delayed over concern for intracranial hemorrhage (ICH) expansion
- Evidence-based practice guidelines do not recommend an optimal prophylaxis treatment regimen
- Some evidence suggests that early initiation of pharmacological prophylaxis ( $\leq 72$  h post-injury) reduces VTE and is safe if ICH is stable on repeat head computed tomography (CT)
- Currently, there is no standard of practice for prescribing pharmacological prophylaxis in patients with TBI at Royal Columbian Hospital (RCH)


## Objectives

- Characterize the prescribing practices of pharmacological prophylaxis in patients with TBI admitted to the intensive care unit (ICU) at RCH
- Characterize the incidence of VTE and the incidence of ICH expansion

## Methods

- Design:** Retrospective chart review at a tertiary care trauma centre
- Population:** Convenience sample of patients with moderate to severe TBI admitted to the ICU at RCH between April 1, 2015 and May 3, 2018
- Inclusion:**
  - > 18 years of age
  - Diagnosis of TBI with ICH on initial head CT
  - Glasgow Coma Score (GCS)  $\leq 12$
- Exclusion:**
  - Death or discharge from ICU within 48 h of injury
  - VTE on admission
  - Chronic anticoagulation use prior to admission
  - ICU admission > 24 h post-injury
- Primary Outcomes:**
  - Proportion of patients that received pharmacological prophylaxis
  - Selection and timing of initiation of pharmacological prophylaxis
- Secondary Outcomes:**
  - Proportion of patients with VTE (DVT and PE) and ICH expansion
    - Before and after pharmacological prophylaxis initiation
    - Early ( $\leq 72$  h post-injury) and late ( $> 72$  h post-injury) pharmacological prophylaxis initiation
- Statistical Analysis:** Descriptive statistics

Figure 1: Patient Screening



## Results

Table 1: Patient Characteristics (n=125)

|  |                  |
|--|------------------|
| Male – no. (%)   | 92 (73.6)        |
| Age (years) – median (range)                                   | 46 (19-90)       |
| Hospital length of stay (days) – median (range)                | 23.1 (2.2-226.1) |
| ICU length of stay (days) – median (range)                     | 6.9 (2-59.4)     |
| Lowest GCS from injury to hospital – median (range)            | 4 (3-12)         |
| Type of ICH on initial CT – no. (%)                            |                  |
| Subarachnoid hemorrhage  | 103 (82.4)       |
| Subdural hematoma  | 83 (66.4)        |
| Contusion  | 48 (38.4)        |
| Intraventricular hemorrhage                                    | 31 (24.8)        |
| Intracerebral hemorrhage                                       | 30 (24)          |
| Epidural hematoma  | 18 (14.4)        |
| No. of risk factors for ICH expansion* – median (range)        | 1 (0-4)          |
| Patients with $\geq 1$ risk factor for ICH expansion – no. (%) | 105 (84)         |
| No. of risk factors for VTE** – median (range)                 | 2 (0-5)          |
| Patients with $\geq 1$ risk factor for VTE – no. (%)           | 118 (94.4)       |

\* ICH expansion risk factors: multiple sites of ICH, epidural or subdural hematoma > 8 mm, neurosurgical intervention  
 \*\* VTE risk factors: age > 60 yrs, pelvic, lower extremity, or spinal fracture, GCS < 8, history of VTE, surgery, BMI > 30 kg/m<sup>2</sup>

Figure 4: VTE and ICH Expansion in Patients that Received Prophylaxis (n=91)




Figure 2: Patients that Received Pharmacological Prophylaxis




Figure 3: Timing of Pharmacological Prophylaxis Initiation (n=91) and First Stable Head CT (n=113)†




Table 2: VTE and ICH Expansion by Timing of Pharmacological Prophylaxis

| Outcome no. (%) | Early ( $\leq 72$ h) (n=19) | Late ( $> 72$ h) (n=72) | No Prophylaxis (n=34) | Total (n=125) |
|-----------------|-----------------------------|-------------------------|-----------------------|---------------|
| VTE             | 6 (31.6)                    | 5 (6.9)                 | 3 (8.8)               | 14 (11.2)     |
| DVT             | 5 (26.3)                    | 4 (5.6)                 | 1 (2.9)               | 10 (8)        |
| PE              | 1 (5.3)                     | 1 (1.4)                 | 2 (5.9)               | 4 (3.2)       |
| ICH expansion   | 10 (52.6)                   | 37 (51.4)               | 21 (61.8)             | 68 (54.4)     |

## Limitations

- Repeat head CT and imaging for VTE ordered at discretion of treating physician
- More patients at higher risk for VTE received pharmacological prophylaxis early
- More patients at higher risk for ICH expansion received pharmacological prophylaxis late or not at all

## Conclusions

- 73% of patients received pharmacological prophylaxis, with 54% initiated in ICU
- The median timing of ICH expansion, first stable head CT, and pharmacological prophylaxis initiation was 0.8, 2, and 5.9 days, respectively
- The overall incidence of VTE was 11.2% and ICH expansion was 54.4%
- Of the patients who received prophylaxis, 42.9% had ICH expansion before and 12.1% had ICH expansion after pharmacological prophylaxis initiation
- Preliminary findings suggest pharmacological prophylaxis may be safely initiated earlier than current practice
- Further research is needed to optimize pharmacological prophylaxis in this population